EUVIMEDEUVIMED entdecken
Crossref

New pyrrole derivatives as DNA gyrase and 14α‐demethylase inhibitors: Design, synthesis, antimicrobial evaluation, and molecular docking

Khaled M H Hilmy iD, Fawzya N M Kishk iD, Esmat B A Shahen, Eman A Sobh iD, Mohamed A Hawata

Drug Development Research · 2023-09 · 84 (6) · 1204-1230

DOI: 10.1002/ddr.22080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 11.05.2023. Verfasst von Khaled M H Hilmy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Science, El-Menoufia University, Shebin El-Kom, Egypt. Hauptthemen laut MEDLINE: 14-alpha Demethylase Inhibitors, DNA Gyrase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An efficient one‐pot reaction utilizing readily available chemical reagents was used to prepare novel 2‐amino‐1,5‐diaryl‐1 H ‐pyrrole‐3‐carbonitrile derivatives and the structures of these compounds were validated by spectroscopic data and elemental analyses. All the synthetic compounds were evaluated for their antimicrobial activities (MZI assay). The tested compounds proved high activities on Staphylococcus aureus (Gram‐positive bacteria) and Candida albicans (Pathogenic fungi). However, they did not show any activity on Escherichia coli (Gram‐negative bacteria). The most effective compounds in MZI assay 7c , 9a , 9b , 11a , and 11b were selected to determine their MIC on S. aureus and C. albicans . Furthermore, DNA gyrase and 14‐ α demethylase inhibitory assays were performed to study the inhibitory activities of 7c , 9a , 9b , 11a , and 11b . The results illustrated that compound 9b was the most DNA gyrase inhibitor (IC 50 of 0.0236 ± 0.45 µM, which was 1.3‐ fold higher than gentamicin reference IC 50 values of 0.0323 ± 0.81 µM). In addition, compound 9b demonstrated the highest 14‐ α demethylase inhibitory effect with IC 50 of 0.0013 ± 0.02 µM, compared to ketoconazole (IC 50 of 0.0008 ± 0.03 µM) and fluconazole (IC 50 of 0.00073 ± 0.01 µM), as antifungal reference drugs. Lastly, docking studies were performed to rationalize the dual inhibitory activities of the highly active compounds on both DNA gyrase and 14‐ α demethylase enzymes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

14-alpha Demethylase InhibitorsDNA GyraseMolecular Docking SimulationStaphylococcus aureusAnti-Bacterial AgentsPyrrolesAntifungal AgentsEscherichia coliMicrobial Sensitivity TestsMolecular StructureStructure-Activity Relationship

Stichwörter der Autor:innen

14-αdemethylaseCandida albicansDNA gyraseStaphylococcus aureusantimicrobialspyrrolesynthesis

Substanzen

14-alpha Demethylase InhibitorsDNA GyraseAnti-Bacterial AgentsPyrrolesAntifungal Agents

Autor:innen und Institutionen

  • Department of Chemistry, Faculty of Science, El-Menoufia University, Shebin El-Kom, Egypt.
  • Depatment of Biochemistry, Faculty of Medicine, Al-Azhar University for Girls, Cairo, Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Menoufia University, Menoufia, Shebin El-Kom, Egypt.

ORCID-Profile: Khaled M H Hilmy, Fawzya N M Kishk, Eman A Sobh

Zitieren

APA

Hilmy, K. M. H., Kishk, F. N. M., Shahen, E. B. A., Sobh, E. A., & Hawata, M. A. (2023). New pyrrole derivatives as DNA gyrase and 14α‐demethylase inhibitors: Design, synthesis, antimicrobial evaluation, and molecular docking. Drug Development Research, 84(6), 1204-1230. https://doi.org/10.1002/ddr.22080

Vancouver

Hilmy KMH, Kishk FNM, Shahen EBA, Sobh EA, Hawata MA. New pyrrole derivatives as DNA gyrase and 14α‐demethylase inhibitors: Design, synthesis, antimicrobial evaluation, and molecular docking. Drug Development Research. 2023;84(6):1204-1230. doi:10.1002/ddr.22080

BibTeX
@article{Hilmy2023,
  author = {Hilmy, Khaled M H and Kishk, Fawzya N M and Shahen, Esmat B A and Sobh, Eman A and Hawata, Mohamed A},
  title = {New pyrrole derivatives as DNA gyrase and 14α‐demethylase inhibitors: Design, synthesis, antimicrobial evaluation, and molecular docking},
  journal = {Drug Development Research},
  year = {2023},
  volume = {84},
  number = {6},
  pages = {1204--1230},
  doi = {10.1002/ddr.22080}
}
Kostenlos starten →